Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedJan 10, 2026
DataAggregated Company Financials
Companies14
  • 7D3.7%
  • 3M11.5%
  • 1Y26.4%
  • YTD3.7%

In the last week, the Pharma industry is up 2.6%, with AstraZeneca up 4.6%. This means that the industry has gained 26% over the past year. Earnings are forecast to grow by 10% annually.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 10 Jan 2026UK£334.6bUK£89.6bUK£14.6b21.5x22.9x3.7x
Mon, 08 Dec 2025UK£321.1bUK£89.8bUK£14.7b21.1x21.9x3.6x
Wed, 05 Nov 2025UK£304.4bUK£89.6bUK£14.0b20.9x21.8x3.4x
Fri, 03 Oct 2025UK£295.3bUK£87.7bUK£11.7b19.4x25.2x3.4x
Sun, 31 Aug 2025UK£280.0bUK£87.4bUK£11.7b21.3x24x3.2x
Tue, 29 Jul 2025UK£263.5bUK£86.9bUK£10.7b29.9x24.6x3x
Thu, 26 Jun 2025UK£256.6bUK£85.9bUK£10.5b25.9x24.3x3x
Sat, 24 May 2025UK£263.4bUK£86.3bUK£10.6b26.9x24.8x3.1x
Mon, 21 Apr 2025UK£252.1bUK£86.5bUK£9.6b26.7x26.3x2.9x
Wed, 19 Mar 2025UK£289.0bUK£87.5bUK£9.6b28.6x30.2x3.3x
Fri, 14 Feb 2025UK£287.8bUK£89.3bUK£9.5b31.1x30.2x3.2x
Sun, 12 Jan 2025UK£233.0bUK£76.6bUK£7.9b32x29.4x3x
Tue, 10 Dec 2024UK£230.1bUK£74.6bUK£7.7b32x29.9x3.1x
Thu, 07 Nov 2024UK£217.1bUK£72.7bUK£7.6b30.5x28.6x3x
Sat, 05 Oct 2024UK£249.3bUK£72.1bUK£9.0b30.3x27.7x3.5x
Mon, 02 Sep 2024UK£280.9bUK£72.0bUK£9.0b42x31.3x3.9x
Wed, 31 Jul 2024UK£259.7bUK£72.3bUK£9.6b34.2x27.1x3.6x
Fri, 28 Jun 2024UK£260.9bUK£71.8bUK£9.6b29.7x27.2x3.6x
Sun, 26 May 2024UK£270.8bUK£71.4bUK£9.6b31.9x28.3x3.8x
Tue, 23 Apr 2024UK£244.3bUK£71.6bUK£9.8b31.8x24.9x3.4x
Thu, 21 Mar 2024UK£234.0bUK£70.3bUK£9.7b31.6x24.1x3.3x
Sat, 17 Feb 2024UK£231.7bUK£69.8bUK£9.6b35.5x24.1x3.3x
Mon, 15 Jan 2024UK£244.2bUK£68.8bUK£10.6b36.8x22.9x3.5x
Wed, 13 Dec 2023UK£228.4bUK£69.4bUK£10.7b33.6x21.3x3.3x
Fri, 10 Nov 2023UK£232.6bUK£70.6bUK£11.0b53.1x21.1x3.3x
Sun, 08 Oct 2023UK£244.8bUK£70.4bUK£10.4b74.9x23.6x3.5x
Tue, 05 Sep 2023UK£236.1bUK£69.2bUK£10.2b53.5x23.2x3.4x
Thu, 03 Aug 2023UK£241.7bUK£68.8bUK£10.2b52.8x23.7x3.5x
Sat, 01 Jul 2023UK£244.6bUK£67.8bUK£7.9b55.1x31x3.6x
Mon, 29 May 2023UK£251.7bUK£68.9bUK£8.0b55.5x31.5x3.7x
Wed, 26 Apr 2023UK£264.6bUK£69.3bUK£6.9b61.8x38.5x3.8x
Fri, 24 Mar 2023UK£240.0bUK£69.7bUK£6.9b58.3x34.8x3.4x
Sun, 19 Feb 2023UK£251.1bUK£70.4bUK£7.2b57.8x34.9x3.6x
Tue, 17 Jan 2023UK£252.7bUK£79.7bUK£6.3b38.3x40x3.2x
Price to Earnings Ratio

40x


Total Market Cap: UK£252.7bTotal Earnings: UK£6.3bTotal Revenue: UK£79.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 27.1x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 22.9x which is lower than its 3-year average PE of 27.1x.
  • The 3-year average PS ratio of 3.4x is lower than the industry's current PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 32% per year over the last three years.
  • Revenues for these companies have grown 4.0% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market1.88%
Healthcare3.67%
Pharma3.68%
Pharma3.68%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AZN AstraZenecaUK£142.164.6%
+UK£9.7b		29.4%PE31.5x
GSK GSKUK£18.863.0%
+UK£2.2b		39.8%PE13.8x
HIK Hikma PharmaceuticalsUK£15.743.3%
+UK£112.9m		-22.2%PE12.6x
HCM HUTCHMED (China)UK£2.176.4%
+UK£111.7m		-12.9%PE5.4x
ANCR Animalcare GroupUK£2.536.3%
+UK£10.4m		3.3%PE58.6x

Latest News

GSK
UK£18.86
GSK
7D
3.0%
1Y
39.8%
HLN
UK£3.68
Haleon
7D
-0.7%
1Y
-1.1%
AZN
UK£142.16
AstraZeneca
7D
4.6%
1Y
29.4%
STX
UK£0.10
Shield Therapeutics
7D
6.6%
1Y
320.0%

STX: Expanded Pediatric And Global Approvals Will Support Future Upside

Analysts have trimmed their price target on Shield Therapeutics slightly, citing updated expectations for revenue growth of about 41.81%, a lower projected profit margin of around 13.33% and a higher future P/E of roughly 17.49x. Together, these factors imply less upside potential from current levels in cash terms than previously estimated.
HCM
UK£2.17
HUTCHMED (China)
7D
6.4%
1Y
-12.9%
HIK
UK£15.74
Hikma Pharmaceuticals
7D
3.3%
1Y
-22.2%

HIK: Leadership Reset And 2030 Revenue Ambition Will Support Earnings Outlook

Analysts have reduced their fair value estimate for Hikma Pharmaceuticals from £22.66 to £22.00 per share, reflecting a combination of more cautious views on management, strategy and catalysts, together with recent recalibrations of price targets across covering banks. Analyst Commentary Recent Street research on Hikma Pharmaceuticals shows a split between more cautious and more optimistic voices, with differing price targets and ratings feeding into the reduced fair value estimate.
ANCR
UK£2.53
Animalcare Group
7D
6.3%
1Y
3.3%
NFX
UK£0.0029
Nuformix
7D
-1.7%
1Y
383.3%
SAR
UK£0.20
Sareum Holdings
7D
17.6%
1Y
-11.1%
IMM
UK£0.073
ImmuPharma
7D
17.7%
1Y
105.6%
N4P
UK£0.005
N4 Pharma
7D
-4.8%
1Y
-16.7%